CAP satellite symposiums are live educational programs with CME funded through a grant by an exhibitor and independently organized by a third party.
Monday, October 22
Personalized Medicine in Oncology enabled by Next-Generation Sequencing
Time: 6:30 pm
This 1.5 hours satellite symposium will provide the learner with an introduction to Genomics and a quick overview of Next-Generation Sequencing (NGS) to better understand the technology that allows sequencing of DNA/RNA much more quickly. The presentation will include specific oncology applications including tumor mutational burden, tumor profiling as it applies to colorectal cancer, and microsatellite instability (MSI), the condition of genetic predisposition to mutation that results from impaired DNA mismatch repair (MMR). The presence of MSI represents that MMR is not functioning normally. It will conclude with a review of the human microbiome, which covers all microbes genes, and immunotherapy.
- Define how genomics and knowledge of DNA has impacted patient care
- Review the broad range of applications and experiments that can be performed with NGS
- Discuss how microsatellite instability and tumor mutational burden test results can help with immunotherapy decisions
CME Accreditation and Designation Statements
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
EXCEL Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This satellite symposium is supported through an educational grant from ILLUMINA.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do
Registration and Dinner: 6:00 PM
Time: 6:30 PM – 8:00 PM
Chair and Presenter:
Lynette M. Sholl, MD
Brigham and Women’s Hospital
Associate Professor, Pathology
Harvard Medical School
Registration and Dinner: 6:00 PM
Symposium: 6:30 PM – 8:00 PM
To register, please visit: www.peerview.com/testEGFR
With the rapid pace of progress in the fields of oncology and pathology, molecular profiling is becoming an integral tool for guiding individualized management of an increasing number of cancers, including lung cancer. Testing to identify EGFR and other key driver mutations is considered essential in advanced NSCLC, and the latest guidelines offer evidence-based recommendations for implementing this in everyday practice. Still, questions remain about the best testing methodologies and workflows to use throughout the continuum of advanced disease. The recent emergence of new, practice-changing data in advanced EGFR-mutant NSCLC and shifts in the treatment landscape also have far-reaching implications for both pathology and oncology practice in terms of what, when, and how to test. Join PeerView Live and our expert-led panel to learn more about the progress in testing and treatment of EGFR-mutant NSCLC, and what this means for pathologists working in various settings.
Upon completion of this activity, participants should be better able to:
- Describe molecular pathways that drive malignancy in lung cancer and oncogenic activation of tyrosine kinases, such as mutations in the EGFR, that have led to the development of specific targeted molecular treatments
- Evaluate current research related to EGFR mutations in the settings of newly diagnosed NSCLC and acquired resistance in the context of the evolving treatment landscape
- Assess the latest clinical data on EGFR-targeted therapy in NSCLC throughout the continuum of disease from the first-line setting to the second-line setting and beyond
- Discuss the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of EGFR mutation status in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance following prior EGFR TKI therapy
- Implement best practices for optimal molecular testing for evaluation of EGFR mutations and interpretation of results to guide treatment decisions throughout the disease continuum of advanced/metastatic NSCLC
Providership, Credit and Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do has been registered as a Lifelong Learning (Part II) to offer 1.5 credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit. Participation information will be shared with ABPath through the ACCME’s Program Reporting and Activity System (PARS). Individual or aggregated participant data may be shared with the funder of the activity
This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.
Tuesday, October 23
Assessing RET-Altered Tumors: An Increasingly Important Target For Personalized Oncology Care
Time: 6:30 pm
It is well-known that point mutations and gene rearrangements/fusions in RET can drive oncogenesis in various solid tumors. However, exciting new data have emerged that suggest selective RET inhibitors have promising anti-tumor activity in patients with these alterations. A critical component of personalized cancer care requires that pathologists understand these new data and, more importantly, are equipped to detect RET alterations so that appropriate patients are offered treatment and enrollment on clinical trials that can improve their clinical outcomes.
This interactive symposium will serve as an ideal forum for attendees to directly engage with and learn from leading pathology experts. Symposium attendees will be provided with a networked all-in-one handheld device that enables them to fully interact, text, and contribute to the symposium cases. This program is designed to provide pathologists insights on the application of the latest clinical data on selective RET inhibitors along with practical guidance to facilitate the detection of RET alterations.
- Discuss the concept of “oncogene addiction” and the dependency on a single activated kinase for proliferation and survival in RET fusion cancers and RET-mutant MTC
- Describe the rationale for reflexive testing of RET in lung and thyroid tumors
- Select evidence-based testing strategies to detect RET fusions and mutations
- Tailor patient treatment protocols using RET inhibitors as part of a multidisciplinary team collaboration
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Loxo Oncology.